UBS Starts Diplomat Pharmacy (DPLO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Mizuho Securities Cuts Price Target as Recent Sell-offs of Specialty Pharma Manufactures Negatively Effect Diplomat Pharmacy (DPLO)
October 21, 2015 6:43 AM EDTMizuho Securities maintained a Buy rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $44.00 (from $53.00), following recent sell-offs of specialty pharmacy manufactures. DPLO does not distribute any VRX or HZNP products. DPLO manages and distributes complex drugs for chronic conditions unlike... More
